Okay this does look like a good announcement.
The journal is a good one, it was only published online today, the quote from John Rasko at the bottom is timely and paints a generous big picture and there is a link to the clinical trial so it ties in academic credibility with practical references readers of either the article (and its open source so free to read without a subscription) or the announcement to the trial.
Good job on this Kilian. It would be rare I think for biotech CEOs to be lead authors in nature medicine publications - I think this is a first for Cynata at least.
Hope it helps the recruitment rate.
Ann: Further GvHD Clinical Data Published in Nature Medicine, page-2
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.0¢ |
Change
-0.005(2.33%) |
Mkt cap ! $37.94M | |||
| Open | High | Low | Value | Volume |
| 21.0¢ | 21.0¢ | 21.0¢ | $423 | 2.016K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 41003 | 20.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 10656 | 1 |
View Market Depth
| Last trade - 12.11pm 27/09/2024 (20 minute delay) ? |
| CYP (ASX) Chart |